Acyclovir Related Published Studies
Well-designed clinical trials related to Acyclovir
Improvement in healing and reduction in HIV shedding with episodic acyclovir therapy as part of syndromic management among men: a randomized, controlled trial. [2009.10.01]
Five-year follow-up on the effect of oral acyclovir after penetrating keratoplasty for herpetic keratitis. [2009.09]
Impact of acyclovir on genital and plasma HIV-1 RNA, genital herpes simplex virus type 2 DNA, and ulcer healing among HIV-1-infected African women with herpes ulcers: a randomized placebo-controlled trial. [2009.07.15]
Valacyclovir and topical clobetasol gel for the episodic treatment of herpes labialis: a patient-initiated, double-blind, placebo-controlled pilot trial. [2009.03]
Double blind trial of adjunctive valacyclovir in individuals with schizophrenia who are seropositive for cytomegalovirus. [2009.02]
Once daily valacyclovir for reducing viral shedding in subjects newly diagnosed with genital herpes. [2009]
A randomised placebo-controlled trial to explore the effect of suppressive therapy with acyclovir on genital shedding of HIV-1 and herpes simplex virus type 2 among Zimbabwean sex workers. [2008.12]
Randomized clinical study comparing Compeed cold sore patch to acyclovir cream 5% in the treatment of herpes simplex labialis. [2008.11]
Protocol for German trial of Acyclovir and corticosteroids in Herpes-simplex-virus-encephalitis (GACHE): a multicenter, multinational, randomized, double-blind, placebo-controlled German, Austrian and Dutch trial [ISRCTN45122933]. [2008.10.29]
Suppressive acyclovir therapy reduces HIV cervicovaginal shedding in HIV- and HSV-2-infected women, Chiang Rai, Thailand. [2008.09.01]
Single-day, patient-initiated famciclovir therapy versus 3-day valacyclovir regimen for recurrent genital herpes: a randomized, double-blind, comparative trial. [2008.09.01]
An international, randomized, double-blind, placebo-controlled, study of valacyclovir for the suppression of herpes simplex virus type 2 genital herpes in newly diagnosed patients. [2008.07]
The effect of daily valacyclovir suppression on herpes simplex virus type 2 viral shedding in HSV-2 seropositive subjects without a history of genital herpes. [2008.03]
Does frequency of genital herpes recurrences predict risk of transmission? Further analysis of the valacyclovir transmission study. [2008.02]
Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation. [2008.01]
Silica gel is as effective as acyclovir cream in patients with recurrent herpes labialis: results of a randomized, open-label trial. [2008]
Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial. [2007.11.15]
Early treatment with prednisolone or acyclovir in Bell's palsy. [2007.10.18]
Valacyclovir treatment in Epstein-Barr virus subset chronic fatigue syndrome: thirty-six months follow-up. [2007.09]
Suppressive Therapy With Valacyclovir in Early Genital Herpes: A Pilot Study of Clinical Efficacy and Herpes-Related Quality of Life. [2007.06]
Bioavailability of two oral suspension and two oral tablet formulations of acyclovir 400 mg: two single-dose, open-label, randomized, two-period crossover comparisons in healthy Mexican adult subjects. [2007.06]
A comparison of one year of episodic or suppressive treatment of recurrent genital herpes with valacyclovir. [2007.05]
A virologic pilot study of valacyclovir in infectious mononucleosis. [2007.05]
Valacyclovir and prednisolone treatment for Bell's palsy: a multicenter, randomized, placebo-controlled study. [2007.04]
Suppressive therapy versus episodic therapy with oral valacyclovir for recurrent herpes labialis: efficacy and tolerability in an open-label, crossover study. [2007.04]
Reactivation of herpes simplex virus type 1 and varicella-zoster virus and therapeutic effects of combination therapy with prednisolone and valacyclovir in patients with Bell's palsy. [2007.01]
A random clinical trial study to assess the efficiency of topical applications of podophyllin resin (25%) versus podophyllin resin (25%) together with acyclovir cream (5%) in the treatment of oral hairy leukoplakia. [2007.01]
Effect of valacyclovir on viral shedding in immunocompetent patients with recurrent herpes simplex virus 2 genital herpes: a US-based randomized, double-blind, placebo-controlled clinical trial. [2006.10]
Comparative efficacy of famciclovir and valacyclovir for suppression of recurrent genital herpes and viral shedding. [2006.09]
Topical iontophoretic administration of acyclovir for the episodic treatment of herpes labialis: a randomized, double-blind, placebo-controlled, clinic-initiated trial. [2006.08.15]
Valacyclovir prophylaxis to prevent recurrent herpes at delivery: a randomized clinical trial. [2006.07]
Improvement of postherpetic neuralgia after treatment with intravenous acyclovir followed by oral valacyclovir. [2006.07]
Pharmacokinetics of acyclovir after single intravenous and oral administration to adult horses. [2006.05]
Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation--a randomized double-blind placebo-controlled study. [2006.03.01]
Interconceptional antibiotics to prevent spontaneous preterm birth: a randomized clinical trial. [2006.03]
Comparison of efficacy of oral valacyclovir and topical acyclovir in the treatment of herpes simplex keratitis: a randomized clinical trial. [2006]
Valacyclovir to expedite the clearance of recurrent herpes gladiatorum. [2005.09]
A comparative randomised study of valacyclovir vs. oral ganciclovir for cytomegalovirus prophylaxis in renal transplant recipients. [2005.09]
A randomized clinical trial of valacyclovir in multiple sclerosis. [2005.06]
Effect of prophylactic valacyclovir on the presence of human herpesvirus DNA in saliva of healthy individuals after dental treatment. [2005.05]
Valacyclovir for cytomegalovirus prophylaxis reduces the risk of acute renal allograft rejection. [2005.02.15]
Prospective comparison of valacyclovir and oral ganciclovir for prevention of cytomegalovirus disease in high-risk renal transplant recipients. [2005]
Well-designed clinical trials possibly related to Acyclovir
Comparison of lavage and swabs for the collection of genital ulcer specimens to measure HIV RNA shedding. [2009.10]
Antiviral agents for treatment of herpes simplex virus infection in neonates. [2009.07.08]
Viremia in acute herpes zoster. [2009.07.01]
Low rate of CMV end-organ disease in HIV-infected patients despite low CD4+ cell counts and CMV viremia: results of ACTG protocol A5030. [2009.05]
Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients. [2009.05]
Treatment of congenital cytomegalovirus infection: implications for future therapeutic strategies. [2009.05]
[Observation on the therapeutic effect of electroacupuncture of Jiaji (EX-B 2) plus regional encircled needling for herpes zoster] [2009.04]
[Pricking blood therapy combined with ultraviolet irradiation for treatment of acute herpes zoster] [2009.04]
Economic evaluation of early administration of prednisolone and/or aciclovir for the treatment of Bell's palsy. [2009.04]
Effect on hearing of ganciclovir therapy for asymptomatic congenital cytomegalovirus infection: four to 10 year follow up. [2009.04]
HSV suppression reduces seminal HIV-1 levels in HIV-1/HSV-2 co-infected men who have sex with men. [2009.02.20]
Impact of aciclovir on genital and plasma HIV-1 RNA in HSV-2/HIV-1 co-infected women: a randomized placebo-controlled trial in South Africa. [2009.02.20]
Slitlamp biomicroscopy and photographic image analysis of herpes simplex virus stromal keratitis. [2009.02]
An assessment of herpesvirus co-infections in patients with CMV disease: correlation with clinical and virologic outcomes. [2009.02]
Results of a phase I/II British Society of Bone Marrow Transplantation study on PCR-based pre-emptive therapy with valganciclovir or ganciclovir for active CMV infection following alemtuzumab-based reduced intensity allogeneic stem cell transplantation. [2009.02]
Risk factors for HIV incidence in women participating in an HSV suppressive treatment trial in Tanzania. [2009.01.28]
Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir. [2009]
Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 coinfected women: a randomized, placebo-controlled, cross-over trial. [2008.12.15]
Prednisolone and valaciclovir in Bell's palsy: a randomised, double-blind, placebo-controlled, multicentre trial. [2008.11]
Cytomegalovirus infection after liver transplantation: current concepts and challenges. [2008.08.21]
Prophylaxis followed by preemptive therapy versus preemptive therapy for prevention of human cytomegalovirus disease in pediatric patients undergoing liver transplantation. [2008.07.15]
Valganciclovir for suppression of human herpesvirus-8 replication: a randomized, double-blind, placebo-controlled, crossover trial. [2008.07.01]
Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. [2008.06.21]
Performance of HerpeSelect and Kalon assays in detection of antibodies to herpes simplex virus type 2. [2008.06]
CMV infections after two doses of daclizumab versus thymoglobulin in renal transplant patients receiving mycophenolate mofetil, steroids and delayed cyclosporine A. [2008.06]
Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial. [2008.05]
Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. [2008.04.10]
Effect of Herpes Simplex Suppression on Incidence of HIV among Women in Tanzania. [2008.03.17]
[Pharmacological treatment of Bell's palsy: favourable effects of prednisolone-based therapy now demonstrated] [2008.02.16]
Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy. [2008.02.15]
Intratympanic application of an antiviral agent for the treatment of Meniere's disease. [2008]
Lack of bioequivalence between two aciclovir tablets in healthy subjects. [2008]
Pharmacokinetics and safety of penciclovir following oral administration of famciclovir to cats. [2007.11]
Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. [2007.09]
Cervicovaginal HIV-1 and herpes simplex virus type 2 shedding during genital ulcer disease episodes. [2007.07.31]
Antiviral agents for the treatment of recurrent respiratory papillomatosis: a systematic review of the English-language literature. [2007.06]
Oral valgancyclovir versus intravenous gancyclovir for cytomegalovirus prophylaxis in kidney transplant recipients. [2007.05]
Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs. [2007.04.15]
Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. [2007.02.22]
Impact of suppressive herpes therapy on genital HIV-1 RNA among women taking antiretroviral therapy: a randomized controlled trial. [2006.11.28]
Bell's palsy: a review of treatment using antiviral agents. [2006.10]
Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. [2006.09]
Reactivation of viruses in solid organ transplant patients receiving cytomegalovirus prophylaxis. [2006.07.27]
Pharmacokinetics of ganciclovir after oral valganciclovir versus intravenous ganciclovir in allogeneic stem cell transplant patients with graft-versus-host disease of the gastrointestinal tract. [2006.06]
The impact of cytomegalovirus disease and asymptomatic infection on acute renal allograft rejection. [2006.06]
Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation. [2006.04.01]
A randomized trial of ganciclovir versus ganciclovir plus immune globulin for prophylaxis against Epstein-Barr virus related posttransplant lymphoproliferative disorder. [2006.03.27]
Therapy of focal viral encephalitis in children with aciclovir and recombinant beta-interferon - results of a placebo-controlled multicenter study. [2005.12.07]
Presence of Epstein-Barr virus and human herpesvirus 6B DNA in multiple sclerosis patients: associations with disease activity. [2005.12]
A surveillance study of adenovirus infection in adult solid organ transplant recipients. [2005.10]
Clinical impact of ganciclovir-resistant cytomegalovirus infections in solid organ transplant patients. [2005.09]
A randomized prospective trial of oral versus intravenous ganciclovir for prophylaxis of cytomegalovirus infection and disease in high-risk kidney recipients. [2005.09]
Simultaneous pancreas-kidney transplantation in a large multicenter study: surgical complications. [2005.07]
Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients. [2005.06.15]
Cytomegalovirus. [2005.06]
Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/R- transplant recipients. [2005.05]
Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation. [2005.05]
Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients. [2005]
|
